Sei Investments Co. Lowers Stock Position in Intuitive Surgical, Inc. $ISRG

Sei Investments Co. cut its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 26.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 409,385 shares of the medical equipment provider’s stock after selling 144,502 shares during the period. Sei Investments Co. owned 0.11% of Intuitive Surgical worth $183,087,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ISRG. SevenBridge Financial Group LLC increased its holdings in shares of Intuitive Surgical by 46.2% in the 3rd quarter. SevenBridge Financial Group LLC now owns 7,944 shares of the medical equipment provider’s stock valued at $3,553,000 after acquiring an additional 2,511 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Intuitive Surgical by 2,871.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 21,219 shares of the medical equipment provider’s stock worth $9,490,000 after purchasing an additional 20,505 shares during the last quarter. Financial Life Planners bought a new stake in Intuitive Surgical during the third quarter valued at about $88,000. RiverPark Advisors LLC boosted its position in Intuitive Surgical by 13.8% during the third quarter. RiverPark Advisors LLC now owns 4,216 shares of the medical equipment provider’s stock valued at $1,886,000 after purchasing an additional 511 shares in the last quarter. Finally, Riverpark Capital Management LLC grew its stake in Intuitive Surgical by 8.3% in the third quarter. Riverpark Capital Management LLC now owns 2,863 shares of the medical equipment provider’s stock valued at $1,280,000 after purchasing an additional 219 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Intuitive Surgical

In other news, EVP Myriam Curet sold 421 shares of Intuitive Surgical stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $494.96, for a total transaction of $208,378.16. Following the completion of the sale, the executive vice president directly owned 409 shares in the company, valued at approximately $202,438.64. The trade was a 50.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gary S. Guthart sold 24,500 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $530.10, for a total transaction of $12,987,450.00. Following the sale, the director directly owned 3,694 shares in the company, valued at $1,958,189.40. This trade represents a 86.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 33,407 shares of company stock worth $17,534,067. Corporate insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Intuitive Surgical in a report on Monday, December 29th. Citigroup raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 price objective on the stock in a research report on Wednesday. Zacks Research upgraded shares of Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 19th. UBS Group set a $570.00 target price on shares of Intuitive Surgical and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Finally, TD Cowen raised shares of Intuitive Surgical to a “strong-buy” rating in a report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $615.86.

Intuitive Surgical Stock Down 2.8%

ISRG opened at $479.27 on Friday. The company has a market cap of $170.20 billion, a P/E ratio of 60.74, a price-to-earnings-growth ratio of 3.80 and a beta of 1.66. The firm’s 50-day moving average price is $515.05 and its 200-day moving average price is $512.37. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. The company had revenue of $2.87 billion during the quarter, compared to analysts’ expectations of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. Intuitive Surgical’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same period last year, the business earned $2.21 EPS. On average, research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Citi upgraded ISRG to Buy with a $590 target, which boosts near‑term sentiment and signals analyst confidence in upside. Citigroup upgrades Intuitive Surgical (ISRG)
• Positive Sentiment: The da Vinci system won FDA clearance for cardiac surgery, opening a much larger TAM (from ~17k to ~160k potential procedures in cleared markets) — a material long‑term growth catalyst if adoption follows. ISRG’s da Vinci Gains FDA Nod for Cardiac Surgery
• Positive Sentiment: Q4 results beat expectations (19% revenue growth, EPS beat) and management highlighted recurring revenue strength — these prints underpin the bullish analyst commentary and recent outperformance days. Intuitive Surgical Inc. stock outperforms competitors
• Neutral Sentiment: Long‑form bulls argue “massive growth ahead” from da Vinci 5, Ion and SP platforms — supportive for the multi‑year case but not a near‑term catalyst. Intuitive Surgical: The Robotic Surgery Leader Still Has Massive Growth Ahead
• Neutral Sentiment: Several valuation pieces note ISRG trades well above historical P/E levels, creating a tension between growth expectations and an elevated multiple — keeps the stock range‑bound absent fresh catalysts. Assessing Intuitive Surgical (ISRG) Valuation
• Negative Sentiment: Management guided for a deceleration in worldwide da Vinci procedure growth in 2026 — a notable near‑term headwind to growth expectations. Intuitive Surgical Stock: Buy, Sell, or Hold?
• Negative Sentiment: Insider selling (multiple senior exec trades in March) is visible and may be fueling profit‑taking and downside pressure despite strong public messaging. SEC filing: Insider Sale Disclosures
• Negative Sentiment: Stock has recently fallen more than the market on low‑volume sessions, indicating short‑term technical weakness and profit‑taking after the post‑earnings run. Intuitive Surgical Suffers a Larger Drop Than the General Market

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.